Glioblastoma Drug Development Summit 2025
ANGLE will be attending the 2025 Glioblastoma Drug Development Summit in Boston, MA.
This summit brings together over 90 industry leaders from pharma, biotech, neuro-oncology, clinical practice, and academia, all united by a shared mission: to revolutionise the future of glioblastoma therapy.
Don’t miss this inspiring opportunity to connect with experts, explore innovative therapeutic approaches, and engage in meaningful discussions on overcoming the challenges in glioblastoma drug development.
Our team will be on hand to showcase how Parsortix® technology could advance the field by potentially enabling real-time, minimally invasive monitoring of glioblastoma through circulating tumour cells (CTCs).
Secure your 1:1 appointment below, and learn more about:
Location
Boston, MA, USA
Date
February 18-20 2025
ANGLE attendees
Request a meeting with our ANGLE attendees.
Brett Swansiger
Chief Commercial Officer
Brett Swansiger is ANGLE’s Chief Commercial Officer, playing a key role in our global corporate partnerships and overseeing our commercial teams in their biopharma services activities and research/clinical product solutions. Brett has over 20 years of commercial leadership, international business development, and business to business sales.
Brett Swansiger
Chief Commercial Officer
Brett Swansiger is ANGLE’s Chief Commercial Officer, playing a key role in our global corporate partnerships and overseeing our commercial teams in their biopharma services activities and research/clinical product solutions. Brett has over 20 years of commercial leadership, international business development, and business to business sales.